A subtle loss: visual and anatomic changes in HIV retinopathy


New technology is allowing clinicians, for the first time, to study the subtle structural changes that cause progression of this disease.

Diagnosing HIV retinopathy

HIV retinopathy is an ischaemic microangiopathy that leads to damage of inner retinal structures including the vasculature and ganglion cells. Clinically, HIV retinopathy is diagnosed by the presence of intra-retinal haemorrhages and soft retinal exudates (cotton wool spots) in patients with low CD4 T-lymphocyte cell counts (<100 or 1.0 x 109/L) in the absence of infectious retinitis. Upon a patient's immune recovery, HIV retinopathy usually resolves within three months. However, if a patient's immune status is not recovered, these signs may persist or worsen while the CD4 cell count remains low.

OCT allows imaging of subtle changes

The advent of more sophisticated retinal imaging technology has opened up new possibilities for studying structural changes in HIV retinopathy. Many of these instruments are already in clinical use for glaucoma and other retinal diseases.

One hypothesis to explain vision loss is that it may be caused by permanent infarctions of the retinal nerve fibre layer from previously resolved cotton wool spots, areas of retinal capillary dropout, or both. Using OCT, we have been able to demonstrate visible inner retinal structural changes long after cotton wool spots have disappeared on ophthalmoscopic examinations. The inner retinal tissue in the area of cotton wool spots remains more dense than adjacent retina (hyper-reflective sign), which may mean chronic oedema or glial transformation of the tissue. It may be that such a cumulative damage from multiple infarctions and haemorrhages can finally lead to changes in the nerve fibre layer of the retina. Fortunately, the progress in technology now means we have the advantage of detecting some of these changes in vivo.

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.